Amylin, Lilly, Alkermes receive FDA complete response letter for Bydureon
Bydureon, an investigational, extended-release medication for type 2 diabetes designed to deliver continuous therapeutic levels of exenatide in a single weekly dose, is the proposed brand name for
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.